Protocols Calculator Guides Glossary About Calculator →
Research use only.  Educational reference. Not medical advice. Not for human consumption.
// catalog · v3

Peptide protocols, indexed.

Research-grade dosage protocols sourced from peer-reviewed literature. Each full protocol contains dosing tables, reconstitution math, mechanism notes, and primary citations.

100+full protocols built
100+peptides cataloged
8research categories
0vendor placements
// 01

Recovery & Tissue Repair

17 protocols
● built
BPC-157 / 5 mg vial
5 mg vial · 3 mL BAC → 1.67 mg/mL · 1 unit = 16.7 mcg
5 mgRUO
→ open protocol
 ● built
BPC-157 / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
BPC-157 / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 67 mcg
20 mgRUO
→ open protocol
 ● built
TB-500 / 5 mg vial
5 mg vial · 2 mL BAC → 2.5 mg/mL · 1 unit = 25 mcg
5 mgRUO
→ open protocol
 ● built
TB-500 / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
TB-500 / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 67 mcg
20 mgRUO
→ open protocol
 ● built
KPV / 10 mg vial
Tripeptide fragment of α-MSH. Studied for anti-inflammatory properties, gut mucosa research, and NF-κB inhibition.
500 mcg–2 mg/daySub-Q · oral
→ open protocol
 ● built
LL-37 / 5 mg vial
Cathelicidin-derived antimicrobial peptide studied for immune modulation, wound healing, and antimicrobial defense.
100–500 mcg/daySub-Q
→ open protocol
 ● built
Thymosin α-1 / 1.6 mg
Immune-modulating peptide from thymosin fraction 5. Studied for immune dysregulation and immune senescence.
1.6 mg 2×/wkSub-Q
→ open protocol
 ● built
VIP / 5 mg vial
Vasoactive Intestinal Peptide. Studied for chronic inflammatory response syndrome (CIRS), immune balance, and anti-inflammatory pathways.
50–250 mcg/dayIntranasal
→ open protocol
 ● built
ARA-290 · Cibinetide / 16 mg
Erythropoietin-derived peptide. Studied for diabetic neuropathy, sarcoidosis-related small-fiber neuropathy, and tissue protection.
4–8 mg/daySub-Q
→ open protocol
● built
ARA-290 / 10 mg vial
10 mg vial of ARA-290 (Cibinetide). EPOR agonist studied for neuropathic pain and tissue repair.
10 mg4–12 mg/dose
→ open protocol
 ● built
Glutathione / 600–1200 mg
Tripeptide master antioxidant. Studied for oxidative-stress reduction, hepatic detoxification support, and immune function.
600–1200 mg/doseSub-Q · IV
→ open protocol
● built
Glutathione / 1,200 mg vial
1,200 mg vial. Master antioxidant — IV or sub-Q for oxidative stress, detoxification, and skin brightening protocols.
1,200 mg600–1,200 mg/dose
→ open protocol
● built
Glutathione / 1,500 mg vial
1,500 mg vial. Highest available concentration for advanced antioxidant and detox protocols.
1,500 mg750–1,500 mg/dose
→ open protocol
 ● built
PNC-27 / 10 mg vial
p53-derived membrane-disrupting peptide. Studied as an investigational anti-cancer compound that selectively targets HDM-2 expressing cells.
10–50 mg/doseSub-Q · IV
→ open protocol
 ● built
MGF / 5 mg vial
Mechano Growth Factor (IGF-1Ec splice variant). Distinct from PEG-MGF — short half-life; localized tissue repair signal. Studied for muscle satellite cell activation.
5 mg100–300 mcg/dayRUO
→ open protocol
// 02

GH Secretagogues & Growth Hormone

17 protocols
● built
CJC-1295 (No DAC) + Ipamorelin / 10 mg blend
GHRH analog + selective GHS. Complementary pathways for synergistic pulsatile GH release.
100–300 mcg ea/dayDaily8–12 wks
→ open protocol
● built
CJC-1295 no-DAC + Ipamorelin / 5 mg/5 mg
5 mg CJC-1295 no-DAC + 5 mg Ipamorelin blend. Same synergistic GHRH+GHRP combination at lower total vial concentration.
10 mg total100–300 mcg/dose
→ open protocol
 ● built
Ipamorelin / 10 mg vial
First selective GH secretagogue. GH release without cortisol/ACTH elevation. Low desensitization profile.
100–300 mcg/dose1–3×/day8–16 wks
→ open protocol
 ● built
GHRP-2 · Pralmorelin / 10 mg
Potent GHRP. Strong GH stimulation via dual pituitary + hypothalamic sites. Mild cortisol/ACTH elevation at higher doses.
100–300 mcg/dose1–3×/day
→ open protocol
 ● built
GHRP-6 / 10 mg vial
Classic GHRP with the strongest appetite stimulation of any secretagogue. Cortisol elevation at high doses.
100–300 mcg/dose2–3×/day
→ open protocol
● built
GHRP-6 / 10 mg vial
10 mg vial of GHRP-6. Strong GH pulse with appetite stimulation via ghrelin pathway. Pairs with GHRH analogs.
10 mg100–300 mcg/dose
→ open protocol
 ● built
Hexarelin / 5 mg vial
Most potent GHRP studied. Strong GH release plus cardioprotective effects. Significant desensitization at chronic high doses.
100–200 mcg/dose2–3×/day
→ open protocol
 ● built
Sermorelin / 10 mg vial
GHRH(1–29) analog. Preserves IGF-1 negative feedback. First GHRH analog studied (pediatric GHD). Before-sleep dosing.
200–500 mcg/dayBefore sleep12–24 wks
→ open protocol
 ● built
CJC-1295 DAC / 2 mg vial
Long-acting GHRH analog with Drug Affinity Complex. ~6–8 day half-life via albumin binding. Once-weekly dosing.
1–2 mg/weekWeekly
→ open protocol
 ● built
CJC-1295 NO DAC / 5 mg vial
Short-acting GHRH analog (~30 min half-life). Produces natural GH pulses. Typically combined with GHRPs.
100–300 mcg/dose1–3×/day
→ open protocol
● built
CJC-1295 no-DAC / 5 mg vial
5 mg vial of CJC-1295 without DAC (Mod GRF 1-29). Short-acting GHRH analog for daily GH pulse protocols.
5 mg100–300 mcg/dose
→ open protocol
 ● built
HGH 191AA / 24 IU vial
24 IU vial · 3 mL BAC → 8 IU/mL · 1 unit = 0.08 IU
24 IURUO
→ open protocol
 ● built
HGH 191AA / 36 IU vial
36 IU vial · 3 mL BAC → 12 IU/mL · 1 unit = 0.12 IU
36 IURUO
→ open protocol
 ● built
Tesamorelin / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
Tesamorelin / 20 mg vial
20 mg vial · 3 mL BAC → 6.67 mg/mL · 1 unit = 67 mcg
20 mgRUO
→ open protocol
 ● built
IGF-1 LR3 / 1 mg vial
Long-acting IGF-1 analog. Downstream GH mediator with extended receptor binding. Direct anabolic and recovery effects.
20–100 mcg/daySub-Q
→ open protocol
 ● built
PEG-MGF / 2 mg vial
PEGylated mechano growth factor. IGF-1 splice variant studied for muscle satellite cell activation and post-injury recovery.
200–400 mcg 2×/wkSub-Q
→ open protocol
 ● built
Follistatin 344 · 315 / 1 mg
Myostatin inhibitor. Studied for muscle hypertrophy via GDF-8 / activin pathway antagonism. Two main isoforms compared.
100 mcg/daySub-Q
→ open protocol
// 03

Metabolic & Weight Management

17 protocols
● built
Retatrutide GLP-3 RT / 5 mg vial
5 mg vial · 0.5 mL BAC → 10 mg/mL · 1 unit = 100 mcg
5 mgRUO
→ open protocol
 ● built
Retatrutide GLP-3 RT / 10 mg vial
10 mg vial · 1 mL BAC → 10 mg/mL · 1 unit = 100 mcg
10 mgRUO
→ open protocol
 ● built
Retatrutide GLP-3 RT / 20 mg vial
20 mg vial · 2 mL BAC → 10 mg/mL · 1 unit = 100 mcg
20 mgRUO
→ open protocol
 ● built
Retatrutide GLP-3 RT / 30 mg vial
30 mg vial · 3 mL BAC → 10 mg/mL · 1 unit = 100 mcg
30 mgRUO
→ open protocol
 ● built
Retatrutide GLP-3 RT / 40 mg vial
40 mg vial · 3 mL BAC → 13.3 mg/mL · 1 unit = 133 mcg
40 mgRUO
→ open protocol
 ● built
Retatrutide GLP-3 RT / 60 mg vial
60 mg vial · 3 mL BAC → 20 mg/mL · 1 unit = 200 mcg
60 mgRUO
→ open protocol
 ● built
Semaglutide GLP-1 SM / 5 mg vial
5 mg vial · 0.5 mL BAC → 10 mg/mL · 1 unit = 100 mcg
5 mgRUO
→ open protocol
 ● built
Semaglutide GLP-1 SM / 10 mg vial
10 mg vial · 1 mL BAC → 10 mg/mL · 1 unit = 100 mcg
10 mgRUO
→ open protocol
 ● built
Semaglutide GLP-1 SM / 20 mg vial
20 mg vial · 2 mL BAC → 10 mg/mL · 1 unit = 100 mcg
20 mgRUO
→ open protocol
● built
GLP1-SM / Semaglutide 10 mg
10 mg semaglutide vial. GLP-1 receptor agonist for metabolic and weight research.
10 mgWeekly
→ open protocol
● built
GLP1-SM / Semaglutide 30 mg
30 mg semaglutide vial. Extended supply for longer GLP-1 research protocols.
30 mgWeekly
→ open protocol
● built
GLP2-TZ / Tirzepatide 10 mg
10 mg tirzepatide (GLP-1/GIP dual agonist) for metabolic research.
10 mgWeekly
→ open protocol
● built
GLP2-TZ / Tirzepatide 20 mg
20 mg tirzepatide vial.
20 mgWeekly
→ open protocol
● built
GLP2-TZ / Tirzepatide 30 mg
30 mg tirzepatide vial.
30 mgWeekly
→ open protocol
● built
GLP2-TZ / Tirzepatide 40 mg
40 mg tirzepatide vial — highest GLP2-TZ concentration available.
40 mgWeekly
→ open protocol
● built
GLP3-RT / Retatrutide 10 mg
10 mg retatrutide (triple GLP-1/GIP/glucagon agonist). Most potent GLP class.
10 mgWeekly
→ open protocol
● built
GLP3-RT / Retatrutide 20 mg
20 mg retatrutide vial.
20 mgWeekly
→ open protocol
● built
GLP3-RT / Retatrutide 30 mg
30 mg retatrutide vial.
30 mgWeekly
→ open protocol
● built
GLP3-RT / Retatrutide 40 mg
40 mg retatrutide vial.
40 mgWeekly
→ open protocol
● built
GLP3-RT / Retatrutide 60 mg
60 mg retatrutide — highest available concentration for advanced research.
60 mgWeekly
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 5 mg vial
5 mg vial · 0.5 mL BAC → 10 mg/mL · 1 unit = 100 mcg
5 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 10 mg vial
10 mg vial · 1 mL BAC → 10 mg/mL · 1 unit = 100 mcg
10 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 15 mg vial
15 mg vial · 1.5 mL BAC → 10 mg/mL · 1 unit = 100 mcg
15 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 20 mg vial
20 mg vial · 2 mL BAC → 10 mg/mL · 1 unit = 100 mcg
20 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 30 mg vial
30 mg vial · 3 mL BAC → 10 mg/mL · 1 unit = 100 mcg
30 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 40 mg vial
40 mg vial · 3 mL BAC → 13.3 mg/mL · 1 unit = 133 mcg
40 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 50 mg vial
50 mg vial · 3 mL BAC → 16.7 mg/mL · 1 unit = 167 mcg
50 mgRUO
→ open protocol
 ● built
Tirzepatide GLP-2 TZ / 60 mg vial
60 mg vial · 3 mL BAC → 20 mg/mL · 1 unit = 200 mcg
60 mgRUO
→ open protocol
 ● built
Mazdutide / 6 mg vial
Dual GLP-1 / glucagon receptor agonist. Phase 3 weight-management investigational compound. Differentiated from triple-agonist class.
0.3–9 mg/weekWeekly
→ open protocol
 ● built
Cagrilintide / 5 mg vial
Long-acting amylin analog. Under investigation in combination with semaglutide (CagriSema). Satiety modulation.
0.3–2.4 mg/weekWeekly
→ open protocol
 ● built
AOD-9604 / 5 mg vial
5 mg vial · 3 mL BAC → 1.67 mg/mL · 1 unit = 16.7 mcg
5 mgRUO
→ open protocol
 ● built
AOD-9604 / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
5-Amino-1MQ / 50 mg vial
NNMT inhibitor studied for adipocyte reduction in metabolic syndrome models. Oral research compound.
50–100 mg/dayOral
→ open protocol
 ● built
AICAR / 50 mg vial
AMPK activator. Studied as an exercise mimetic — increasing fatty-acid oxidation and endurance capacity in preclinical models.
100–500 mg/daySub-Q
→ open protocol
 ● built
SLU-PP-332 / 10 mg vial
ERR (estrogen-related receptor) agonist. Novel exercise-mimetic compound studied for muscle endurance and fat oxidation.
10–25 mg/daySub-Q
→ open protocol
 ● built
MIC + Lipo-C + B12
Lipotropic blend of methionine, inositol, choline, plus B12. Studied for hepatic fat metabolism support and energy.
1 mL/wkIM · Sub-Q
→ open protocol
 ● built
Survodutide / 10 mg vial
GLP-1/glucagon dual agonist. Phase 2: 12.5–14.9% weight loss over 46 weeks. Weekly titration 0.6→6 mg.
10 mgWeeklyRUO
→ open protocol
 ● built
Adipotide / 10 mg vial
⚠ Prohibitin-targeting peptidomimetic. Destroys adipose vasculature. Clinical development discontinued due to renal toxicity.
10 mg250 mcg–1 mg/dayRUO
→ open protocol
 ● built
L-Carnitine / 200 mg vial
Mitochondrial fatty-acid transporter. Sub-Q bypasses TMAO production of oral route. 100% bioavailability.
200 mg50–200 mg/dayRUO
→ open protocol
● built
Lipo-B / MIC + B12
Compounded lipotropic blend of methionine, inositol, choline, and B12. Hepatic fat metabolism support. Pre-mixed.
1 mL/wkIM · Sub-Q
→ open protocol
● built
Lipo-C / MIC + L-Carnitine
Lipotropic blend with L-Carnitine for mitochondrial fatty-acid transport. Supports hepatic fat export and β-oxidation. Pre-mixed.
1–2 mL2–3×/wkIM · Sub-Q
→ open protocol
● built
Vitamin B12 / Cyanocobalamin
Injectable cobalamin. Near-100% bioavailability regardless of intrinsic factor status. Supports methylation and neurological function.
1,000 mcg/doseWeekly
→ open protocol
● built
Lipo-B / MIC + B12
Compounded lipotropic blend of methionine, inositol, choline, and B12. Hepatic fat metabolism support. Pre-mixed — no reconstitution.
1 mL/wkIM · Sub-Q
→ open protocol
● built
Lipo-C / MIC + L-Carnitine
Lipotropic blend with L-Carnitine for mitochondrial fatty-acid transport. Supports hepatic fat export and β-oxidation. Pre-mixed — no reconstitution.
1–2 mL2–3×/wkIM · Sub-Q
→ open protocol
● built
Vitamin B12 / Cyanocobalamin
Injectable cobalamin. Near-100% bioavailability regardless of intrinsic factor status. Supports methylation, neurological function, and red blood cell synthesis.
1,000 mcg/doseWeekly
→ open protocol
 ● built
Lipo-B / MIC + B12
Compounded lipotropic blend of methionine, inositol, choline, and B12. Hepatic fat metabolism support. Pre-mixed — no reconstitution.
1 mL/wkIM · Sub-Q
→ open protocol
 ● built
Lipo-C / MIC + L-Carnitine
Lipotropic blend with L-Carnitine for mitochondrial fatty-acid transport. Supports hepatic fat export and β-oxidation. Pre-mixed — no reconstitution.
1–2 mL2–3×/wkIM · Sub-Q
→ open protocol
 ● built
Vitamin B12 / Cyanocobalamin
Injectable cobalamin. Near-100% bioavailability regardless of intrinsic factor. Supports methylation, neurological function, and red blood cell synthesis.
1,000 mcg/doseWeekly
→ open protocol
// 04

Longevity & Bioregulators

17 protocols
● built
Epitalon / 10 mg vial
10 mg vial · 2 mL BAC → 5 mg/mL · 1 unit = 50 mcg
10 mgRUO
→ open protocol
 ● built
Epitalon / 50 mg vial
50 mg vial · 3 mL BAC → 16.7 mg/mL · 1 unit = 167 mcg
50 mgRUO
→ open protocol
 ● built
FOXO4-DRI / 10 mg vial
FOXO4-p53 disruptor. Studied as a senolytic agent — selectively inducing apoptosis in senescent cells.
1–5 mg/injection3-day cycleMonthly
→ open protocol
 ● built
SS-31 · Elamipretide / 10 mg vial
10 mg vial · 1 mL BAC → 10 mg/mL · 1 unit = 100 mcg
10 mgRUO
→ open protocol
 ● built
SS-31 · Elamipretide / 50 mg vial
50 mg vial · 3 mL BAC → 16.7 mg/mL · 1 unit = 167 mcg
50 mgRUO
→ open protocol
 ● built
MOTS-c / 10 mg vial
10 mg vial · 3 mL BAC → 3.33 mg/mL · 1 unit = 33 mcg
10 mgRUO
→ open protocol
 ● built
MOTS-c / 40 mg vial
40 mg vial · 3 mL BAC → 13.3 mg/mL · 1 unit = 133 mcg
40 mgRUO
→ open protocol
 ● built
MOTS-c (40 mg vial / 4 mL Option)
40 mg vial · 4 mL BAC → 10.0 mg/mL · 1 unit = 100 mcg · 3 baseline + 3 Advanced charts
40 mg4 mLRUO
→ open protocol
 ● built
NAD+ / 500 mg vial
500 mg vial · 3 mL BAC → 167 mg/mL · 1 unit = 1.67 mg
500 mgRUO
→ open protocol
 ● built
NAD+ / 1000 mg vial
1000 mg vial · 3 mL BAC → 333 mg/mL · 1 unit = 3.33 mg
1000 mgRUO
→ open protocol
 ● built
Humanin / 5 mg vial
Mitochondrial-derived neuroprotective peptide. Studied for Alzheimer's models, metabolic regulation, and aging biomarkers.
100–250 mcg/daySub-Q
→ open protocol
 ● built
Pinealon / 20 mg vial
Tripeptide bioregulator from pineal gland. Studied for circadian regulation, sleep architecture, and neuroretinal aging.
0.1–0.5 mg/daySub-Q
→ open protocol
 ● built
Cartalax / 20 mg vial
Tripeptide bioregulator from cartilage. Studied for musculoskeletal aging and connective tissue gene expression.
0.1–0.5 mg/daySub-Q
→ open protocol
 ● built
Chonluten / 20 mg vial
Tripeptide bioregulator from bronchial mucosa. Studied for respiratory epithelial aging and pulmonary biomarkers.
0.1–0.5 mg/daySub-Q
→ open protocol
 ● built
Bronchogen / 20 mg vial
Tetrapeptide bioregulator. Studied for bronchial epithelium repair, pulmonary function, and respiratory aging biomarkers.
0.1–0.5 mg/daySub-Q
→ open protocol
 ● built
Prostamax / 20 mg vial
Tripeptide bioregulator. Studied for prostate-tissue gene expression and male reproductive-tissue aging biomarkers.
0.1–0.5 mg/daySub-Q
→ open protocol
 ● built
Cortagen / 20 mg vial
Cortical tetrapeptide bioregulator (Ala-Glu-Asp-Pro). Studied for cognitive support and post-stroke neural recovery.
500 mcg/day20-day cycleSub-Q
→ open protocol
 ● built
Ovagen / 20 mg vial
Hepatic tripeptide bioregulator (Glu-Asp-Leu). Studied for liver support and detoxification pathway modulation.
500 mcg/day20-day cycleSub-Q
→ open protocol
 ● built
Testagen / 20 mg vial
Testicular tetrapeptide bioregulator (Lys-Glu-Asp-Gly). Studied for male reproductive support and testosterone axis modulation.
500 mcg/day20-day cycleSub-Q
→ open protocol
 ● built
Vesugen / 20 mg vial
Vascular tripeptide bioregulator (Lys-Glu-Asp). Studied for endothelial repair and cardiovascular aging.
500 mcg/day20-day cycleSub-Q
→ open protocol
 ● built
Vilon / 20 mg vial
Immune dipeptide bioregulator (Lys-Glu). Studied for T-cell function and age-related immunosenescence.
500 mcg/day20-day cycleSub-Q
→ open protocol
 ● built
Livagen / 20 mg vial
Lymphoid tetrapeptide bioregulator (Lys-Glu-Asp-Ala). Studied for B-cell activity and humoral immune support.
500 mcg/day20-day cycleSub-Q
→ open protocol
// 05

Skin & Cosmetic Peptides

6 protocols
● built
GHK-Cu / 50 mg vial
50 mg vial · 3 mL BAC → 16.7 mg/mL · 1 unit = 167 mcg
50 mgRUO
→ open protocol
 ● built
GHK-Cu / 100 mg vial
100 mg vial · 3 mL BAC → 33.3 mg/mL · 1 unit = 333 mcg
100 mgRUO
→ open protocol
 ● built
AHK-Cu / 50 mg vial
Copper tripeptide cousin of GHK-Cu. Primarily studied for hair follicle stimulation and dermal capillary health.
0.5–2 mg/dayTopical · Sub-Q
→ open protocol
 ● built
Melanotan I · Afamelanotide / 10 mg
Selective MC1R agonist. studied for erythropoietic protoporphyria. Studied for tanning and photoprotection.
0.5–1 mg/daySub-Q
→ open protocol
 ● built
Melanotan II / 10 mg vial
Non-selective melanocortin receptor agonist. Studied for skin pigmentation, photoprotection, and sexual function.
0.25–1 mg/daySub-Q
→ open protocol
 ● built
SNAP-8 / 10 mg vial (topical)
⚠ Topical only — do not inject. Acetyl octapeptide-3 for expression-line reduction. Formulate at 0.0015–0.005% in cream/serum.
10 mgTopicalRUO
→ open protocol
● built
SNAP-8 / 100 mg vial
100 mg vial — 10 mL BAC → 10 mg/mL. High-volume cosmetic peptide vial for extended wrinkle-reduction protocols.
100 mg4–10 mcg/cm²
→ open protocol
// 06

Hormonal & Sexual Health

7 protocols
● built
HCG / 5000 IU vial
Human chorionic gonadotropin. LH-mimetic. studied for cryptorchidism and hypogonadism. Testosterone support and fertility research.
250–1500 IU/dose2–3×/wk
→ open protocol
 ● built
HMG / 75 IU vial
Human menopausal gonadotropin. FSH + LH combination studied for ovarian stimulation and fertility research applications.
75–150 IU/daySub-Q · IM
→ open protocol
 ● built
PT-141 · Bremelanotide / 10 mg
Melanocortin agonist (MC3R/MC4R). investigational compound studied for HSDD. CNS sexual arousal mechanism.
1.0–2.0 mg/dosePRNMax 1×/24h
→ open protocol
 ● built
Gonadorelin / 2 mg vial
GnRH decapeptide. Stimulates pulsatile LH and FSH release from pituitary. HPG axis research.
100 mcg/pulsePulsatile
→ open protocol
 ● built
Kisspeptin-10 / 10 mg vial
GPR54 receptor agonist. Upstream GnRH pulse inducer. Studied for LH pulsatility and reproductive hormone research.
1–2 nmol/kgSub-Q
→ open protocol
 ● built
Oxytocin / 10 IU vial
Nonapeptide neuromodulator. Studied for social bonding, anxiety reduction, and stress regulation. Intranasal and sub-Q routes.
5–40 IU/doseIntranasal · Sub-Q
→ open protocol
● built
Oxytocin / 5 mg vial
5 mg vial — 3 mL BAC water → 1.67 mg/mL. 16.7 mcg per U-100 unit. Titration 100→500 mcg/day sub-Q or intranasal.
5 mg100–500 mcg/day
→ open protocol
● built
Oxytocin / 10 mg vial
10 mg vial — 3 mL BAC water → 3.33 mg/mL. 33.3 mcg per U-100 unit. Titration 100→500 mcg/day sub-Q or intranasal.
10 mg100–500 mcg/day
→ open protocol
// 07

Cognitive & Neuroprotective

17 protocols
● built
Cerebrolysin / 60 mg vial
Porcine brain-derived neuropeptide mixture. Studied for neuroprotection, neuroplasticity, and recovery from neural injury.
5–30 mL/dayIV · IM10–21 day cycle
→ open protocol
 ● built
Semax / 30 mg vial
Synthetic heptapeptide ACTH analog. Studied for cognitive enhancement, neuroprotection, and BDNF upregulation.
300–600 mcg/dayIntranasal
→ open protocol
● built
Semax / 10 mg vial
10 mg vial. ACTH-derived nootropic. Intranasal or sub-Q. Studied for BDNF upregulation and cognitive enhancement.
10 mg300–900 mcg/day
→ open protocol
● built
Semax / 30 mg vial
30 mg vial — extended supply for longer Semax protocols or higher-dose cognitive research.
30 mg300–1,500 mcg/day
→ open protocol
 ● built
ADAMAX / 30 mg vial
Modified Semax analog with extended half-life. Studied for cognitive enhancement, BDNF upregulation, and neuroprotective signaling.
300–600 mcg/dayIntranasal
→ open protocol
 ● built
Selank / 5 mg vial
Synthetic tuftsin analog with anxiolytic and cognitive effects. Studied for anxiety, stress, and immune function.
250–3000 mcg/dayIntranasal · Sub-Q
→ open protocol
● built
Selank / 10 mg vial
10 mg vial. Synthetic anxiolytic heptapeptide. Sub-Q or intranasal. Studied for anxiety, cognition, and immune modulation.
10 mg250–500 mcg/day
→ open protocol
● built
Selank / 30 mg vial
30 mg vial — extended supply for longer Selank protocols or higher-dose intranasal research.
30 mg250–1,000 mcg/day
→ open protocol
 ● built
DSIP / 5 mg vial
5 mg vial · 2 mL BAC → 2.5 mg/mL · 1 unit = 25 mcg
5 mgRUO
→ open protocol
 ● built
DSIP / 15 mg vial
15 mg vial · 3 mL BAC → 5 mg/mL · 1 unit = 50 mcg
15 mgRUO
→ open protocol
 ● built
Dermorphin / 5 mg vial
Heptapeptide opioid agonist (mu-receptor). Studied as an investigational analgesic with potency multiples greater than morphine.
100–500 mcg/doseSub-Q
→ open protocol
 ● built
PE-22-28 · Spadin Analog / 10 mg
TREK-1 channel inhibitor. Studied as a fast-acting investigational antidepressant in preclinical models.
100–500 mcg/daySub-Q · Intranasal
→ open protocol
● built
Neuroxelin / 48 mg blend
Proprietary neuropeptide blend for cognitive support and neuroprotection. Combines cerebrolysin-derived fractions with nootropic peptides.
2–5 mL/day10–21 day cycle
→ open protocol
● built
Neuroxelin / 48 mg blend
Proprietary neuropeptide blend for cognitive support and neuroprotection. Combines cerebrolysin-derived fractions with nootropic peptides.
2–5 mL/day10–21 day cycle
→ open protocol
 ● built
Neuroxelin / 48 mg blend
Proprietary neuropeptide blend studied for cognitive support and neuroprotection. Combines cerebrolysin-derived fractions with nootropic peptides.
2–5 mL/day10–21 day cycle
→ open protocol
// 08

Peptide Blends

14 protocols
● built
BPC-157 + TB-500 / 20 mg blend
High-dose recovery blend: 10 mg BPC-157 + 10 mg TB-500. Standard and loading-phase protocols. Complementary tissue-repair mechanisms.
500–1000 mcg/day4–8 wks
→ open protocol
● built
Wolverine Blend / 5 mg vial
5 mg vial (2.5 mg BPC-157 + 2.5 mg TB-500). 2 mL BAC → 2.5 mg/mL. Titration 500–750 mcg/day sub-Q.
5 mg500–750 mcg/day
→ open protocol
 ● built
BPC-157 + TB-500 / 10 mg blend
Lighter 10 mg version: 5 mg BPC-157 + 5 mg TB-500. For lower doses or shorter cycles.
250–500 mcg/day4–6 wks
→ open protocol
● built
Wolverine Blend / 20 mg vial
20 mg vial (10 mg BPC-157 + 10 mg TB-500). 4 mL BAC → 5 mg/mL. Highest-concentration Wolverine for extended recovery cycles.
20 mg750–1,000 mcg/day
→ open protocol
 ● built
CJC-1295 (No DAC) + Ipamorelin / 10 mg
GHRH analog + selective GHS. Synergistic pulsatile GH release via complementary receptor activation.
100–300 mcg ea/day8–12 wks
→ open protocol
 ● built
Semaglutide + Cagrilintide · CagriSema
GLP-1 agonist + amylin analog. Phase 3 investigation. Dual satiety mechanism for weight management research.
Variable titrationWeekly
→ open protocol
 ● built
GHRP-2 + CJC-1295 / 10 mg blend
Potent GHRP + GHRH combination for amplified GH pulse. Classic synergistic secretagogue pairing.
100–300 mcg ea/dose2–3×/day
→ open protocol
 ● built
Tesamorelin + Ipamorelin / 10 mg blend
GHRH analog with strongest visceral fat evidence (HIV lipodystrophy trials) + selective GHRP. Synergistic GH release.
2 mg + 300 mcg/doseDaily
→ open protocol
 ● built
4× Blend
Four-peptide stack combining tissue repair and recovery agents in a single reconstituted vial. Synergistic mechanisms for accelerated repair research.
VariableDaily
→ open protocol
 ● built
GLOW Blend
Skin & longevity blend pairing GHK-Cu with complementary peptides. Studied for collagen synthesis, skin remodeling, and gene-expression modulation.
1–2 mg/daySub-Q
→ open protocol
 ● built
KLOW Blend
Multi-peptide combination blend for systemic recovery and tissue support. Combines complementary peptide mechanisms in a single vial.
VariableDaily
→ open protocol
● built
RTE60 Blend (GLP3-RT 20mg + GLP2-TZ 40mg)
Triple+dual GLP agonist blend — Retatrutide 20mg + Tirzepatide 40mg in one vial for comprehensive metabolic research.
60 mg totalWeekly
→ open protocol
● built
Dihexa / 5 mg vial
Nootropic peptide derived from angiotensin IV. Studied for cognitive enhancement and neuroplasticity.
5 mgSub-Q or Oral
→ open protocol
● built
Matrixyl / 10 mg vial
Palmitoyl Pentapeptide-4. Collagen-stimulating cosmetic peptide studied for fine line and wrinkle reduction.
10 mgTopical · Sub-Q
→ open protocol
● built
PTD-DM / 10 mg vial
Research peptide studied for neuroprotective and cognitive applications.
10 mgSub-Q
→ open protocol
● built
HCG / 10,000 IU vial
10,000 IU vial of Human Chorionic Gonadotropin. Double-strength for extended hormonal protocols.
10,000 IUSub-Q · IM
→ open protocol
● built
Semax + Selank Blend / 20 mg
Dual nootropic-anxiolytic blend: Semax (BDNF upregulation) + Selank (anxiolysis). Cognitive focus with anxiety reduction.
20 mg (10+10)Intranasal · Sub-Q
→ open protocol
● built
Tri-Heal / TB-500 + BPC-157 + KPV
Triple recovery blend: TB-500 + BPC-157 + KPV. Broader repair than Wolverine blend.
500–1,500 mcg/day4–8 wks
→ open protocol
● built
Melanotan II + PT-141 Blend / 20 mg
Dual melanocortin blend: MT-II (tanning) + PT-141 (sexual function). Lower per-component doses.
0.5–1 mg/dosePRN
→ open protocol
● built
CJC-1295 DAC + Ipamorelin Blend
Long-acting GHRH once weekly + selective daily GHRP. Sustained background + daily GH pulses.
CJC 1–2 mg/wkIpa 200–300 mcg/day
→ open protocol
● built
AOD-9604 + CJC-1295 + Ipamorelin / 12 mg
Triple fat-loss + GH blend. AOD lipolysis + CJC GHRH + Ipamorelin GHRP. Daily fasted.
600–1,200 mcg/dayFasted
→ open protocol
● built
Relaxation PM Blend
Pre-sleep: DSIP + Selank + optional Oxytocin/Epitalon. Studied for sleep quality and pre-sleep anxiety.
Sub-Q · Intranasal30–60 min before sleep
→ open protocol
● built
Tri-Heal / TB-500 + BPC-157 + KPV
Triple recovery blend: TB-500 (cell migration) + BPC-157 (cytoprotection) + KPV (NF-κB inhibition). Broader repair than Wolverine.
500–1,500 mcg/day4–8 wks
→ open protocol
● built
Melanotan II + PT-141 Blend / 20 mg
Dual melanocortin blend: MT-II (MC1R tanning) + PT-141 (MC3R/MC4R sexual function). Complementary activation at lower per-component doses.
0.5–1 mg/dosePRN
→ open protocol
● built
CJC-1295 DAC + Ipamorelin Blend
Long-acting GHRH once weekly + selective daily GHRP. Sustained background + daily GH pulses for synergistic secretagogue research.
CJC 1–2 mg/wkIpa 200–300 mcg/day
→ open protocol
● built
AOD-9604 + CJC-1295 + Ipamorelin / 12 mg
Triple fat-loss + GH blend: AOD-9604 lipolysis + CJC GHRH + Ipamorelin GHRP. Daily fasted administration for body composition research.
600–1,200 mcg/dayFasted8–12 wks
→ open protocol
● built
Relaxation PM Blend
Pre-sleep blend: DSIP (slow-wave sleep) + Selank (anxiolytic) + optional Oxytocin/Epitalon. Studied for sleep quality and pre-sleep anxiety.
Sub-Q · Intranasal30–60 min before sleep
→ open protocol
 ● built
Tri-Heal / TB-500 + BPC-157 + KPV
Triple recovery blend: TB-500 (cell migration) + BPC-157 (cytoprotection) + KPV (NF-κB inhibition). Broader repair coverage than Wolverine.
500–1,500 mcg/day4–8 wks
→ open protocol
 ● built
Melanotan II + PT-141 Blend / 20 mg
Dual melanocortin blend: MT-II (MC1R tanning) + PT-141 (MC3R/MC4R sexual function). Complementary activation at lower per-component doses.
0.5–1 mg/dosePRN
→ open protocol
 ● built
CJC-1295 DAC + Ipamorelin Blend
Long-acting GHRH (once weekly via DAC) + selective daily GHRP. Sustained GHRH background + daily GH pulses.
CJC 1–2 mg/wkIpa 200–300 mcg/day
→ open protocol
 ● built
AOD-9604 + CJC-1295 + Ipamorelin / 12 mg
Triple fat-loss + GH blend: AOD-9604 (lipolysis) + CJC No-DAC (GHRH) + Ipamorelin (selective GHRP). Daily fasted administration.
600–1,200 mcg/dayFasted8–12 wks
→ open protocol
 ● built
Relaxation PM Blend
Pre-sleep blend: DSIP (slow-wave sleep) + Selank (anxiolytic) + optional Oxytocin/Epitalon. Studied for sleep quality and pre-sleep anxiety.
Sub-Q · Intranasal30–60 min before sleep
→ open protocol